Cover Image
市場調查報告書

再生醫療市場分析:產品,治療領域,地區別預測

Regenerative Medicine Market Analysis By Product (Therapeutics {Primary Cell-based, Stem Cell-based, Immunotherapies, & Gene Therapies}, Tools, Banks, & Services), By Therapeutic Category, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 544778
出版日期 內容資訊 英文 250 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
再生醫療市場分析:產品,治療領域,地區別預測 Regenerative Medicine Market Analysis By Product (Therapeutics {Primary Cell-based, Stem Cell-based, Immunotherapies, & Gene Therapies}, Tools, Banks, & Services), By Therapeutic Category, And Segment Forecasts, 2014 - 2025
出版日期: 2017年07月21日 內容資訊: 英文 250 Pages
簡介

本報告提供再生醫療的全球市場調查,提供整體市場趨勢,各產品·治療領域,地區別詳細趨勢,市場變化與預測,推動市場要素及阻礙因素分析,競爭環境,主要企業簡介等系統性資訊。

第1章 調查手法

第2章 摘要整理

第3章 再生醫療市場趨勢

  • 市場區隔·範圍
    • 推動市場要素
    • 市場阻礙因素
  • 市場滲透度·成長預測的製圖
  • SWOT分析
  • 波特的五力分析
  • 企業的開發平台分析
  • 法規環境
    • 美國
    • 加拿大
    • 歐洲
    • 日本
    • 中國

第4章 再生醫療市場分析:各產品

  • 市場趨勢分析:各產品
  • 治療方法
    • 第一代培養細胞法
    • 基幹細胞·前驅細胞療法
    • 免疫細胞療法
    • 基因治療
  • 醫療設備
  • 再生醫療銀行
  • 服務

第5章 再生醫療市場分析:各治療領域

  • 市場趨勢分析:各治療領域
  • 皮膚
  • 肌肉骨骼
  • 免疫·發炎
  • 癌症
  • 心血管
  • 其他

第6章 再生醫療市場分析:各地區

  • 各地區的市場佔有率
  • 北美
    • 北美的再生醫療市場:各產品
    • 北美的再生醫療市場:各治療領域
    • 美國的再生醫療市場
    • 加拿大的再生醫療市場
  • 歐洲
    • 歐洲的再生醫療市場:各產品
    • 歐洲的再生醫療市場:各治療領域
    • 德國的再生醫療市場
    • 英國的再生醫療市場
  • 亞太地區
    • 亞太地區的再生醫療市場:各產品
    • 亞太地區的再生醫療市場:各治療領域
    • 日本的再生醫療市場
    • 中國的再生醫療市場
  • 南美
    • 南美的再生醫療市場:各產品
    • 南美的再生醫療市場:各治療領域
    • 巴西的再生醫療市場
  • 中東·非洲
    • 中東·非洲的再生醫療市場:各產品
    • 中東·非洲的再生醫療市場:各治療領域
    • 南非的再生醫療市場

第7章 競爭環境

  • 策略的組成架構
  • 參與企業的區分
  • 企業簡介
目錄
Product Code: GVR-1-68038-952-4

The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. Increased prevalence of neurodegenerative, orthopedic, and other aging-related disorders in geriatric population coupled with rising global geriatric population is anticipated to drive market growth.

Developments in biotechnology have enabled gaining in-depth knowledge pertaining to cell division and differentiation as well as the metabolism mechanism of various cells. This enriched knowledge, coupled with emergence of novel streams of biotechnology such as gene therapy and nanotechnology, further prospered use of cell-based technology in therapeutic treatment.

Well established regenerative approached for various dermatological indications exists since ages. Technological advances introduced scaffolds, matrices, and grafts engineered for faster regeneration and minimal surgical procedure.

Identification of ability of stem cells to develop into various different cell lines further propelled the advancements in regenerative medicine. Frequent media exposure due to regulatory as well as ethical controversies around embryonic stem cells has increased awareness among the masses. This encouraged researchers to explore and develop other potential fields for similar applications, such as induced pluripotent stem cells (iPSC).

Furthermore, the emergence of gene therapy techniques with potential to rectify and restore effects of gene mutations in cells is under development. Conditions caused due to Single Nucleotide Polymorphism (SNP) as well as mutations that induce degenerative characteristics are primarily targeted.

Biologics, individually or in combination with cells or devices, are explored to support regenerate the biological functions of cells, tissues, or organs. A number of combinatorial therapies to support chemotherapy and other cancer treatments by prevention as well as treatment for cancer relapse are in development phases.

In addition, rising prevalence of complicated degenerative disorders such as age-related macular degeneration, Alzheimer's disease, and Parkinson's disease, especially in the aging population resulted in high investments in R&D to develop therapeutic solutions.

Regenerative medicine grabs the attention of the healthcare industry owing to its promising applications along with significant advances in supportive fields including tissue engineering, stem cells, gene therapy, drug discovery and nanotechnology. For instance, 3D printing over scaffold with stem cells to restore structure as well as functional characteristics of biological cells, tissues, and organs.

Further key findings from the report suggest:

The global regenerative medicine demand exceeded USD 1.7 billion in 2016 and is expected to grow at a considerable rate over the forecast period owing to the presence of a strong looking product pipeline with anticipated commercializations just around the corner

Therapeutics emerged as the largest product segment in 2016 as it has a relatively high implementation and usage rate resulting in higher adoption

Global regenerative services demand for facilities such as tissue banks and cellular engineering tools is expected to drive demand in the segment

The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies with increased focus of dominant players in emerging economies is attributive to market growth. market.

Key players including Asterias Bio, Athersys, Integra LifeSciences Corpotation, and MiMedx are involved in complex technical cum financial partnerships with larger players in an attempt to expedite R&D

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information Procurement
    • 1.1.1. Purchased Database
    • 1.1.2. GVR's Internal Database
  • 1.2. Data Analysis
  • 1.3. Market Formulation & Validation
  • 1.4. Approaches for Market Estimation
    • 1.4.1. Approach 1: Commodity Flow & Bottom Up Approach
    • 1.4.2. Approach 2: Top Down and Parent Market Analysis

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Regenerative Medicnie Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Presence of strong pipeline portfolio and high number of clinical trials
      • 3.1.1.1.1 Major milestones & key events in regenerative medicine
      • 3.1.1.2 High economic impact of regenerative medicine
      • 3.1.1.3 Emerging applications of gene therapy in regenerative medicine
      • 3.1.1.4 High investment & funding to support development of RM
      • 3.1.1.5 Technological advances in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
      • 3.1.1.6 Presence of strategic partnerships to accelerate development & commercialization of regenerative medicine
      • 3.1.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 High cost of treatment
      • 3.1.2.2 Regulatory issues pertaining stem cell, tissues engineering and regenerative medicine
      • 3.1.2.3 Ethical issues related to use of stem cell & regenerative medicines for R&D
  • 3.2 Penetration & Growth Prospect Mapping for Therapeutic Category, 2016
  • 3.3 Regenerative Medicine -SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.4 Industry Analysis - Porter's
  • 3.5 Regenerative Medicine: Pipeline Analysis
    • 3.5.1 Astellas Pharma Inc.
    • 3.5.2 Bayer AG
    • 3.5.3 AstraZeneca
    • 3.5.4 F. Hoffmann-La Roche Ltd
    • 3.5.5 Pfizer Inc.
    • 3.5.6 Merck & Co., Inc.
    • 3.5.7 Abbott (St. Jude Children's Research Hospital)
    • 3.5.8 Vericel Corporation
    • 3.5.9 Novartis AG
    • 3.5.10 GlaxoSmithKline plc.
    • 3.5.11 Baxter
    • 3.5.12 Boehringer Ingelheim GmbH
    • 3.5.13 Amgen Inc.
    • 3.5.14 Eli Lilly and Company
    • 3.5.15 Bristol-Myers Squibb Company
    • 3.5.16 TAKARA BIO INC.
    • 3.5.17 Vital Therapies, Inc. (VTL)
    • 3.5.18 Swedish Orphan Biovitrum
    • 3.5.19 Stratatech Corporation
    • 3.5.20 Stempeutics Research Pvt. Ltd
    • 3.5.21 Soluble Systems, LLC
    • 3.5.22 Smith & Nephew plc
    • 3.5.23 Shire Pharmaceuticals Group PLC
    • 3.5.24 Beike Biotechnology Co., Ltd.
    • 3.5.25 SanBio, Inc.
    • 3.5.26 ReNeuron Group plc
    • 3.5.27 Regeneus Ltd.
    • 3.5.28 Regen BioPharma, Inc
    • 3.5.29 Q Therapeutics, Inc.
    • 3.5.30 Promethera Biosciences
    • 3.5.31 Pluristem Therapeutics, Inc. (PSTI)
    • 3.5.32 Pharmicell Co., Ltd.
    • 3.5.33 Osiris Therapeutics, Inc.
    • 3.5.34 Orthofix International NV
    • 3.5.35 Orthocell Limited
    • 3.5.36 Takeda Pharmaceutical Company Limited
    • 3.5.37 Caladrius
    • 3.5.38 U.S. Stem cell Inc.
    • 3.5.39 Cesca Therapeutics
    • 3.5.40 Osiris Therapeutics Inc.
    • 3.5.41 Astellas
    • 3.5.42 Opex Therapeutics, Inc.
    • 3.5.43 Northern Therapeutics, Inc.
    • 3.5.44 Northern Therapeutics, Inc.
    • 3.5.45 Neuralstem Inc.
    • 3.5.46 Multigene Vascular Systems, Inc.
    • 3.5.47 MEDIPOST Co.Ltd.
    • 3.5.48 Mesoblast Ltd.
    • 3.5.49 MacroCure, Inc.
    • 3.5.50 Living Cell Technologies, Ltd.
  • 3.6 Regulatory Environment
    • 3.6.1 Regulatory environment: U.S.
    • 3.6.2 Regulatory environment: Canada
    • 3.6.3 Regulatory environment: Europe
    • 3.6.4 Regulatory environment: Japan
      • 3.6.4.1 Regenerative Medicine: Risk classification technique
    • 3.6.5 Regulatory environment: China

Chapter 4 Regenerative Medicine Market: Product Type Estimates & Trend Analysis

  • 4.1 Regenerative Medicine Market: Product Type Movement Analysis
  • 4.2 Therapeutics
    • 4.2.1 Global regenerative medicine therapeutics market, 2014 - 2025 (USD Million)
    • 4.2.2 Primary cell-based therapeutics
      • 4.2.2.1 Global primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.2.2 Dermatology
      • 4.2.2.2.1 Various approaches for skin regeneration
      • 4.2.2.2.2 Global dermatology primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.2.3 Musculoskeletal
      • 4.2.2.3.1 Global musculoskeletal primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.2.4 Surgical
      • 4.2.2.4.1 Global surgical primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.2.5 Dental
      • 4.2.2.5.1 Global dental primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.2.6 Others
      • 4.2.2.6.1 Global other primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    • 4.2.3 Stem cell & progenitor cell-based therapeutics
      • 4.2.3.1 Global stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.3.2 Autologous
      • 4.2.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.3.3 Allogeneic
      • 4.2.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
      • 4.2.3.4 Others
      • 4.2.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
    • 4.2.4 Cell-based Immunotherapies
      • 4.2.4.1 Global cell-based immunotherapies market, 2014 - 2025 (USD Million)
    • 4.2.5 Gene Therapies
      • 4.2.5.1 Global gene therapies market, 2014 - 2025 (USD Million)
  • 4.3 Tools
    • 4.3.1 Global regenerative medicines tools market, 2014 - 2025 (USD Million)
  • 4.4 Banks
    • 4.4.1 Global cell banks market, 2014 - 2025 (USD Million)
  • 4.5 Services
    • 4.5.1 Global regenerative medicine services market, 2014 - 2025 (USD Million)

Chapter 5 Regenerative Medicine Market: Therapeutic Category Estimates & Trend Analysis

  • 5.1 Regenerative Medicine Market: Therapeutic Category Movement Analysis
  • 5.2 Dermatology
    • 5.2.1 Global dermatological therapeutics market, 2014 - 2025 (USD Million)
  • 5.3 Musculoskeletal
    • 5.3.1 Global musculoskeletal therapeutics market, 2014 - 2025 (USD Million)
  • 5.4 Immunology & Inflammation
    • 5.4.1 Global immunology & inflammation therapeutics market, 2014 - 2025 (USD Million)
  • 5.5 Oncology
    • 5.5.1 Global oncology therapeutics market, 2014 - 2025 (USD Million)
  • 5.6 Cardiovascular
    • 5.6.1 Global cardiovascular therapeutics market, 2014 - 2025 (USD Million)
  • 5.7 Ophthalmology
    • 5.7.1 Global ophthalmology therapeutics market, 2014 - 2025 (USD Million)
  • 5.8 Others
    • 5.8.1 Global other therapeutics market, 2014 - 2025 (USD Million)

Chapter 6 Regenerative Medicine Market: Regional Estimates & Trend Analysis, by Product And Therapeutic Category

  • 6.1 Regenerative Medicine Market Share by Region, 2016 & 2025
  • 6.2 North America
    • 6.2.1 North America regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    • 6.2.2 North America regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.2.3 U.S.
      • 6.2.3.1 U.S. regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.2.3.2 U.S. regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.2.4 Canada
      • 6.2.4.1 Canada regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.2.4.2 Canada regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    • 6.3.2 Europe regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.3.3.2 Germany regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.3.4 UK
      • 6.3.4.1 UK regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.3.4.2 UK regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    • 6.4.2 Asia Pacific regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.4.3 Japan
      • 6.4.3.1 Japan regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.4.3.2 Japan regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.4.4 China
      • 6.4.4.1 China regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.4.4.2 China regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    • 6.5.2 Latin America regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.5.3 Brazil
      • 6.5.3.1 Brazil regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.5.3.2 Brazil regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
  • 6.6 Middle East & Africa
    • 6.6.1 Middle East & Africa regenerative medicines market,by product type, 2014 - 2025 (USD Million)
    • 6.6.2 Middle East & Africa regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)
    • 6.6.3 South Africa
      • 6.6.3.1 South Africa regenerative medicines market,by product type, 2014 - 2025 (USD Million)
      • 6.6.3.2 South Africa regenerative medicines market,by therapeutic category, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
  • 7.2 Market Participation Categorization
  • 7.3 Company Profiles
    • 7.3.1 Integra LifeSciences Corporation
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product benchmarking
      • 7.3.1.4 Strategic initiatives
    • 7.3.2 Astellas Pharma Inc.
      • 7.3.2.1 Company overview
      • 7.3.2.1.1 Ocata Therapeutics, Inc.
      • 7.3.2.2 Financial performance
      • 7.3.2.2.1 Financial Performance
      • 7.3.2.3 Product benchmarking
      • 7.3.2.4 Strategic initiatives
    • 7.3.3 Corline Biomedical AB
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product benchmarking
      • 7.3.3.4 Strategic initiatives
    • 7.3.4 COOK BIOTECH, INC.
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product benchmarking
      • 7.3.4.4 Strategic initiatives
    • 7.3.5 Bayer BV
      • 7.3.5.1 Company overview
      • 7.3.5.1.1 BlueRock Therapeutics
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product benchmarking
      • 7.3.5.4 Strategic initiatives
    • 7.3.6 AstraZeneca
      • 7.3.6.1 Company overview
      • 7.3.6.1.1 MedImmune
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product benchmarking
      • 7.3.6.4 Strategic initiatives
    • 7.3.7 F. Hoffmann-La Roche Ltd
      • 7.3.7.1 Company overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Product benchmarking
      • 7.3.7.4 Strategic initiatives
    • 7.3.8 Pfizer Inc.
      • 7.3.8.1 Company overview
      • 7.3.8.2 Financial performance
      • 7.3.8.3 Product benchmarking
      • 7.3.8.4 Strategic initiatives
    • 7.3.9 Merck & Co., Inc.
      • 7.3.9.1 Company overview
      • 7.3.9.1.1 Sigma-Aldrich Co. LLC
      • 7.3.9.1.2 Merck Millipore
      • 7.3.9.2 Financial performance
      • 7.3.9.2.1 Financial performance
      • 7.3.9.3 Product benchmarking
      • 7.3.9.4 Strategic initiatives
    • 7.3.10 Abbott
      • 7.3.10.1 Company overview
      • 7.3.10.1.1 St. Jude Medical, Inc.
      • 7.3.10.2 Financial performance
      • 7.3.10.2.1 Financial performance
      • 7.3.10.3 Product benchmarking
    • 7.3.11 Vericel Corporation
      • 7.3.11.1 Company overview
      • 7.3.11.2 Financial performance
      • 7.3.11.3 Product benchmarking
      • 7.3.11.4 Strategic initiatives
    • 7.3.12 Novartis AG
      • 7.3.12.1 Company overview
      • 7.3.12.1.1 Alcon
      • 7.3.12.2 Financial performance
      • 7.3.12.3 Product benchmarking
      • 7.3.12.4 Strategic initiatives
    • 7.3.13 GlaxoSmithKline plc.
      • 7.3.13.1 Company overview
      • 7.3.13.2 Financial performance
      • 7.3.13.3 Product benchmarking
      • 7.3.13.4 Strategic initiatives
    • 7.3.14 Baxter.
      • 7.3.14.1 Company overview
      • 7.3.14.1.1 Synovis Micro Companies Alliance Inc
      • 7.3.14.2 Financial performance
      • 7.3.14.3 Product benchmarking
    • 7.3.15 Boehringer Ingelheim GmbH(C.H.Boehringer Sohn AG & Co.KG, Ingelheim)
      • 7.3.15.1 Company overview
      • 7.3.15.2 Financial performance
      • 7.3.15.3 Product benchmarking
      • 7.3.15.4 Strategic initiatives
    • 7.3.16 Amgen Inc.
      • 7.3.16.1 Company overview
      • 7.3.16.2 Financial performance
      • 7.3.16.3 Product benchmarking
      • 7.3.16.4 Strategic initiatives
    • 7.3.17 Eli Lilly and Company
      • 7.3.17.1 Company overview
      • 7.3.17.2 Financial performance
      • 7.3.17.3 Product benchmarking
      • 7.3.17.4 Strategic initiatives
    • 7.3.18 Bristol-Myers Squibb Company
      • 7.3.18.1 Company overview
      • 7.3.18.1.1 iPierian, Inc
      • 7.3.18.2 Financial performance
      • 7.3.18.3 Product benchmarking
      • 7.3.18.4 Strategic initiatives
    • 7.3.19 Nuvasive, Inc.
      • 7.3.19.1 Company overview
      • 7.3.19.2 Financial performance
      • 7.3.19.3 Product benchmarking
      • 7.3.19.4 Strategic initiatives
    • 7.3.20 Organogenesis, Inc.
      • 7.3.20.1 Company overview
      • 7.3.20.1.1 NuTech
      • 7.3.20.2 Financial performance
      • 7.3.20.2.1 Financial performance
      • 7.3.20.3 Product benchmarking
      • 7.3.20.4 Strategic initiatives
    • 7.3.21 MiMedx Group, Inc.
      • 7.3.21.1 Company overview
      • 7.3.21.1.1 Stability, LLC.
      • 7.3.21.2 Financial performance
      • 7.3.21.3 Product benchmarking
      • 7.3.21.4 Strategic initiatives
    • 7.3.22 TAKARA BIO INC.
      • 7.3.22.1 Company overview
      • 7.3.22.2 Financial performance
      • 7.3.22.3 Product benchmarking
      • 7.3.22.4 Strategic initiatives
    • 7.3.23 Caladrius Biosciences, Inc.
      • 7.3.23.1 Company overview
      • 7.3.23.2 Financial performance
      • 7.3.23.3 Product benchmarking
      • 7.3.23.4 Strategic initiatives
    • 7.3.24 U.S. Stem Cell, Inc.
      • 7.3.24.1 Company overview
      • 7.3.24.2 Financial performance
      • 7.3.24.3 Product benchmarking
      • 7.3.24.4 Strategic initiatives
    • 7.3.25 Cesca Therapeutics
      • 7.3.25.1 Company overview
      • 7.3.25.2 Financial performance
      • 7.3.25.3 Product benchmarking
      • 7.3.25.4 Strategic initiatives
    • 7.3.26 Osiris Therapeutics, Inc
      • 7.3.26.1 Company overview
      • 7.3.26.2 Financial performance
      • 7.3.26.3 Product benchmarking
      • 7.3.26.4 Strategic initiatives

List of Tables

  • TABLE 1 U.S.: Estimated costs involved in disease area and their associated cell- and gene-based therapies
  • TABLE 2 Global landscape: Number of regenerative medicine companies including cell therapeutic companies
  • TABLE 3 2016: Clinical trials in industry by technology type
  • TABLE 4 Tax incentives for life science R&D in leading countries
  • TABLE 5 Deaths attributable to neurological disorders as percentage of total deaths
  • TABLE 6 Estimated prevalence and number of people with diabetes (adult 18+ years)
  • TABLE 7 Global cancer incidences, 2016
  • TABLE 8 Summary of cystic fibrosis foundation patient registry (2014 & 2015)
  • TABLE 9 Regulatory status of cell-based tissue engineering & regenerative medicine
  • TABLE 10 FDA stratification of somatic cell therapy products based on intended use and extent of manipulation
  • TABLE 11 Collaborative networks and infrastructures that support regenerative medicine in Canada
  • TABLE 12 State Food and Drug Administration (SFDA) approved stem cell products
  • TABLE 13 Stem cell research institutes in China
  • TABLE 14 SFDA approved tissue-engineering products
  • TABLE 15 Regenerative medicine used in patients
  • TABLE 16 Various approaches in regenerative medicine for dermatological use
  • TABLE 17 Various types of scaffolds in in vitro study
  • TABLE 18 Predicted prevalence of Osteoporosis and Low Bone Mass for 2010 & 2030
  • TABLE 19 Prevalence of ophthalmic diseases in U.S
  • TABLE 20 Global burden of neurological diseases: Projected number of Disability Adjusted Life Years (DALYs) for neurological disorders
  • TABLE 21 North America: Clinical studies using HCT for hematopoietic and non-hematopoietic conditions (2016)
  • TABLE 22 North America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 23 North America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 24 North America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 25 North America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 26 North America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 27 U.S. regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 28 U.S. regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 29 U.S. primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 30 U.S. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 31 U.S. regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 32 Projected economic output of Canada's stem cell industry between 2015 and 2025
  • TABLE 33 Canada regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 34 Canada regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 35 Canada primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 36 Canada stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 37 Canada regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 38 Europe regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 39 Europe regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 40 Europe primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 41 Europe stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 42 Europe regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 43 Germany regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 44 Germany regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 45 Germany primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 46 Germany stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 47 Germany regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 48 UK: National action in regenerative medicine
  • TABLE 49 UK: Funds for regenerative medicine research: 2012-2017 (in USD million)
  • TABLE 50 UK regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 51 UK regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 52 UK primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 53 UK stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 54 UK regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 55 Asia Pacific regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 56 Asia Pacific regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 57 Asia Pacific primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 58 Asia Pacific stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 59 Asia Pacific regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 60 Japan regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 61 Japan regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 62 Japan primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 63 Japan stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 64 Japan regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 65 Main monographs published in china
  • TABLE 66 China regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 67 China regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 68 China primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 69 China stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 70 China regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 71 Latin America: Current initiatives and opportunities
  • TABLE 72 Latin America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 73 Latin America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 74 Latin America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 75 Latin America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 76 Latin America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 77 Brazil regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 78 Brazil regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 79 Brazil primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 80 Brazil stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 81 Brazil regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 82 Middle East & Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 83 Middle East & Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 84 Middle East & Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 85 Middle East & Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 86 Middle East & Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 87 South Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 88 South Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 89 South Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 90 South Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 91 South Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Trends in clinical trials in 2014, 2015, & 2016
  • FIG. 12 Investments in regenerative medicine in 2014, 2015, & 2016
  • FIG. 13 Shows the data on Prevalence of chronic diseases in U.S.
  • FIG. 14 Shows global data on deaths caused by diseases in 2015 (In Millions).
  • FIG. 15 Market restraint relevance analysis (Current & future impact)
  • FIG. 16 Penetration & growth prospect mapping for therapeutic category, 2016
  • FIG. 17 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 18 Porter's Five Forces Analysis
  • FIG. 19 Regenerative Medicine: Risk classification technique
  • FIG. 20 Global regenerative medicine market: Product type outlook key takeaways
  • FIG. 21 Global regenerative medicine market: Product type movement analysis
  • FIG. 22 Global regenerative medicine therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 23 Global primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 24 Various approaches for skin regeneration
  • FIG. 25 Global dermatology primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 26 Global musculoskeletal primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 27 Global surgical primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 28 Global dental primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 29 Global other primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 30 Global stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 31 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 32 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 33 Global other stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 34 Global cell-based immunotherapies market, 2014 - 2025 (USD Million)
  • FIG. 35 Global gene therapies market, 2014 - 2025 (USD Million)
  • FIG. 36 Global regenerative medicines tools market, 2014 - 2025 (USD Million)
  • FIG. 37 Global cell banks market, 2014 - 2025 (USD Million)
  • FIG. 38 Global regenerative medicine services market, 2014 - 2025 (USD Million)
  • FIG. 39 Global regenerative medicine market: Therapeutic category outlook key takeaways
  • FIG. 40 Global regenerative medicine market: Therapeutic category movement analysis
  • FIG. 41 Global dermatological therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 42 Predicted prevalence of Osteoporosis and Low Bone Mass from 2010 to 2030
  • FIG. 43 Global musculoskeletal therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 44 Global immunology & inflammation therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 45 Global oncology therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 46 Global cardiovascular therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 47 Global ophthalmology therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 48 Global other therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 49 Regional market place: Key takeaway
  • FIG. 50 Regenerative medicine regional outlook, 2016 & 2025
  • FIG. 51 North America regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 52 U.S regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 53 Canada regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 54 Europe regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 55 Germany regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 56 UK regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 57 Asia Pacific regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 58 Japan regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 59 China regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 60 Latin America regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 61 Brazil regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 62 Middle East & Africa regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 63 South Africa regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 64 Strategy framework
  • FIG. 65 Participant categorization
Back to Top